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OBJECTIVE: To report efficacy and tolerance of interleukin 1 blockade in adult
patients with mevalonate kinase deficiency (MKD).
METHODS: We retrospectively collected data on 13 patients with MKD who had
received anakinra (n = 10) and canakinumab (n = 7).
RESULTS: Anakinra resulted in complete or partial remission in 3/10 and 5/10
patients, respectively, and no efficacy in 2/10, but a switch to canakinumab led to
partial remission. Canakinumab resulted in complete or partial remission in 3/7
and 4/7 patients, respectively.
CONCLUSION: These data support frequent partial responses, showing a better
response with canakinumab. The genotype and therapeutic outcomes correlation
should help in the personalization of treatment.
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